UB Paderborn / Katalog / Suche / in CDI

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2134-2139

2012

Link zum Volltext

Verfügbarkeit prüfen

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

Leukemia research, 2017-05, Vol.56, p.88-95

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

Leukemia research, 2014-02, Vol.38 (2), p.149-154

2014

Link zum Volltext

Verfügbarkeit prüfen

The palatability and tolerability of deferasirox taken with different beverages or foods

Pediatric blood & cancer, 2013-09, Vol.60 (9), p.1507-1512

2013

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Blood, 2014-12, Vol.124 (21), p.1350-1350

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Blood, 2014-12, Vol.124 (21), p.4890-4890

2014

Link zum Volltext

Verfügbarkeit prüfen

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

Blood, 2013-11, Vol.122 (21), p.2775-2775

2013

Link zum Volltext

Verfügbarkeit prüfen

A 36-month analysis of treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes from a prospective observational study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7122-7122

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study to Evaluate Overall Response Rates in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine with or without Deferasirox

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.S48-S48

2015

Link zum Volltext

Verfügbarkeit prüfen

The palatability and tolerability of deferasirox taken with different beverages or foods: Palatability and Tolerability of Deferasirox

Pediatric blood & cancer, 2013-09, Vol.60 (9), p.1507-1512

2013

Link zum Volltext

Verfügbarkeit prüfen

Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

Blood, 2012-11, Vol.120 (21), p.3800-3800

2012

Link zum Volltext

Verfügbarkeit prüfen

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Blood, 2012-11, Vol.120 (21), p.1010-1010

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Blood, 2013-11, Vol.122 (21), p.988-988

2013

Link zum Volltext

Verfügbarkeit prüfen

Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial

Blood, 2011-11, Vol.118 (21), p.1060-1060

2011

Link zum Volltext

Verfügbarkeit prüfen

24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients

Blood, 2011-11, Vol.118 (21), p.2800-2800

2011

Link zum Volltext

Verfügbarkeit prüfen

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Blood, 2010-11, Vol.116 (21), p.5155-5155

2010

Link zum Volltext

Verfügbarkeit prüfen

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study

Blood, 2009-11, Vol.114 (22), p.3829-3829

2009

Link zum Volltext

Verfügbarkeit prüfen

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Blood, 2008-11, Vol.112 (11), p.634-634

2008

Link zum Volltext

Verfügbarkeit prüfen

Iron Parameters in 84 MDS Patients Enrolled in a Deferasirox (Exjade®, ICL670) Multicenter Trial

Blood, 2006-11, Vol.108 (11), p.4847-4847

2006

Link zum Volltext

Verfügbarkeit prüfen

Increased Mitochondrial Oxidative Stress in the Sod2 (+/-) Mouse Results in the Age-Related Decline of Mitochondrial Function Culminating in Increased Apoptosis

Proceedings of the National Academy of Sciences - PNAS, 2001-02, Vol.98 (5), p.2278-2283

2001

Link zum Volltext

Verfügbarkeit prüfen

Two New Species and New Records of Sepsidae from the Brazilian Amazon

Journal of medical entomology, 2022-09, Vol.59 (5), p.1548-1555

2022

Link zum Volltext

Verfügbarkeit prüfen

Diversity, Virulence, and Antimicrobial Resistance in Isolates From the Newly Emerging Klebsiella pneumoniae ST101 Lineage

Frontiers in microbiology, 2019-04, Vol.10, p.542-542

2019

Link zum Volltext

Verfügbarkeit prüfen

Reliability of 3D Gait Data across Multiple Laboratories

Gait & posture, 2016-09, Vol.49, p.375-381

2016

Link zum Volltext

Verfügbarkeit prüfen

Biomechanical risk factors for knee osteoarthritis when using passive and powered ankle–foot prostheses

Clinical biomechanics (Bristol), 2014-12, Vol.29 (10), p.1186-1192

2014

Link zum Volltext

Verfügbarkeit prüfen

Experimental comparisons of passive and powered ankle-foot orthoses in individuals with limb reconstruction

Journal of neuroengineering and rehabilitation, 2018-11, Vol.15 (1), p.111-111, Article 111

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

The palatability and tolerability of deferasirox taken with different beverages or foods

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

A 36-month analysis of treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes from a prospective observational study

A Phase 2 Study to Evaluate Overall Response Rates in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine with or without Deferasirox

The palatability and tolerability of deferasirox taken with different beverages or foods: Palatability and Tolerability of Deferasirox

Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial

24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Iron Parameters in 84 MDS Patients Enrolled in a Deferasirox (Exjade®, ICL670) Multicenter Trial

Increased Mitochondrial Oxidative Stress in the Sod2 (+/-) Mouse Results in the Age-Related Decline of Mitochondrial Function Culminating in Increased Apoptosis

Two New Species and New Records of Sepsidae from the Brazilian Amazon

Diversity, Virulence, and Antimicrobial Resistance in Isolates From the Newly Emerging Klebsiella pneumoniae ST101 Lineage

Reliability of 3D Gait Data across Multiple Laboratories

Biomechanical risk factors for knee osteoarthritis when using passive and powered ankle–foot prostheses

Experimental comparisons of passive and powered ankle-foot orthoses in individuals with limb reconstruction

Suchergebnisse filtern